CD274 and non-small cell lung carcinoma: Therefore the field of immuno-oncology has rapidly evolved for NSCLC, and immune-based therapies, including immune checkpoint inhibitors (ICIs) such as antibodies against programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1), have emerged as exciting therapeutic approaches (1).